TA Associates invests in Taiwanese tea brand Gong cha

TA Associates invests in Taiwanese tea brand Gong cha

Taiwanese tea brand Gong cha Group has closed an undisclosed investment from global growth private equity firm TA Associates. Established in 2006, Gong cha offers tea, products, and services by procuring ingredients from selected suppliers and giving customers freshly brewed tea. The company’s main product is the Taiwanese-style bubble tea, which is sweet milk tea […]

Rinchem to open hazardous materials warehouse in Taiwan

Rinchem to open hazardous materials warehouse in Taiwan

Rinchem said that it will open a new hazardous materials warehouse in Taiwan to be located in Tainan, as per the latest chemical industry news. The hazardous materials warehouse will be the second such facility for Rinchem, which is engaged in provides customized warehousing and transportation solutions for hazardous materials. The first facility has been […]

Changhua Windfarm Phase 1 : Heerema bags contract for installation of jacket foundations

Changhua Windfarm Phase 1 : Heerema bags contract for installation of jacket foundations

Jan de Nul’s Taiwan branch has selected Heerema Marine Contractors to install 21 jacket foundations (4 legged) for the 110MW Changhua Windfarm Phase 1 offshore wind project. Taiwan Power Company (TPC) is the owner of Changhua Windfarm Phase 1 located offshore Taiwan, 8km off the coast of Changhua county. The Taiwanese offshore wind project is […]

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising lung cancer drug D-0316. Under this agreement, InventisBio has out-licensed the rights to D-0316 in China, Hong Kong, and Taiwan to Betta Pharmaceuticals Co., Ltd. in a deal valued at […]

TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for the treatment of inherited Epidermolysis Bullosa (EB). This trial marks a significant advancement in the quest for effective therapies for this challenging condition. The Phase 2 trial of AC-203 is […]

1 3 4 5